<DOC>
	<DOCNO>NCT02283671</DOCNO>
	<brief_summary>First human study ass tolerability safety profile treatment dendritic cell patient multiple sclerosis neuromyelitis optica .</brief_summary>
	<brief_title>Treatment Multiple Sclerosis Neuromyelitis Optica With Regulatory Dendritic Cell : Clinical Trial Phase 1 B</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>patient Multiple sclerosis neuromyelitis optica diagnose year inclusion Expanded Disability Status Scale 3.0 8.5 subtypes multiple sclerosis Neuromyelitis optica Multiple Sclerosis patient previously offer therapeutic alternative available indication either decline receiving treatment least 6 month outbreak increase least 1 point Expanded Disability Status Scale ( EDSS ) ( nonresponders ) tolerate treatment Patients Neuromyelitis optica ( NMO ) stable immunomodulatory treatment past 6 month without treatment candidate receive Corticosteroid treatment last 30 day Presence outbreak last month Inability perform brain Magnetic resonance imaging ( paramagnetic contrast ) Serious systemic disease , include Hepatitis B virus , Hepatitis C Virus , Human Immunodeficiency Virus . Uncontrolled hypertension , insulindependent diabetes mellitus , heart disease kidney failure severe respiratory Personal history cancer family history know hereditary cancer patient participate experimental study last 3 month woman childbearingaged use effective contraceptive method pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>